Alto Neuroscience, Inc. Common Stock (NY:ANRO)

24.12 -0.68 (-2.74%)

Delayed Quote Updated: 10:48 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alto Neuroscience, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Important Notice to Long-Term Shareholders of Alto Neuroscience, Inc. (NYSE: ANRO); Luminar Technologies, Inc. (NASDAQ: LAZR); Replimune Group, Inc. (NASDAQ: REPL); and RxSight, Inc. (NASDAQ: RXST): Grabar Law Office is Investigating Claims on Your Behalf

July 27, 2025

From Grabar Law Office

Via GlobeNewswire

ANRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Alto Neuroscience, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit

July 25, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

ANRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Alto Neuroscience, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit

July 25, 2025

Via TheNewswire.com

Topics Lawsuit

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

July 25, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

Alto Neuroscience, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 19, 2025 to Discuss Your Rights - ANRO

July 25, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

Alto Neuroscience, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 19, 2025 to Discuss Your Rights - ANRO

July 25, 2025

Via TheNewswire.com

Topics Fraud Lawsuit

Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc.and Certain Officers – ANRO

July 23, 2025

From Pomerantz LLP

Via GlobeNewswire

ALTO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Alto Neuroscience, Inc. (ANRO) and Encourages Investors to Contact the Firm

July 22, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

ALTO NEUROSCIENCE, INC. (NYSE: ANRO) INVESTOR ALERT Investors With Large Losses in Alto Neuroscience, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

July 22, 2025

From Bernstein Liebhard LLP

Via GlobeNewswire

ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm

July 22, 2025

From The Schall Law Firm

Via Business Wire

Rosen Law Firm Urges Alto Neuroscience, Inc. (NYSE: ANRO) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

July 22, 2025

From The Rosen Law Firm, P.A.

Via Business Wire

Shareholder Alert: Robbins LLP Informs Investors of the Alto Neuroscience, Inc. Class Action

July 21, 2025

From Robbins LLP

Via GlobeNewswire

Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression

June 30, 2025

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203

June 26, 2025

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Adds 'Intriguing' Depression Asset Via Over $100 Million Deal ↗

June 03, 2025

Alto Neuroscience acquires Chase's treatment-resistant depression drug portfolio for $1.75 million upfront; early data shows strong efficacy for lead candidate ALTO-207.

Via Benzinga

Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway

June 03, 2025

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder

May 29, 2025

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience to Participate in Upcoming Investor Conferences

May 28, 2025

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 14, 2025

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Presents New Data at the Society of Biological Psychiatry Annual Meeting Underscoring Precision Psychiatry Approach

April 28, 2025

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day

April 22, 2025

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights

March 20, 2025

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Is Down Nearly 35% This Year, But Retail Traders Keep Flocking To Micro-Cap Stock ↗

March 03, 2025

While ALTO-100's Phase 2 results failed to meet expectations, the company has emphasized the potential of ALTO-300, another MDD treatment currently in Phase 2b trials.

Via Stocktwits

Alto Neuroscience to Participate in Upcoming Investor Conferences

February 25, 2025

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker

February 19, 2025

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial

February 12, 2025

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Investors With Losses Are Invited To Contact The Schall Law Firm

December 16, 2024

Via ACCESSWIRE

This Addus HomeCare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

December 16, 2024

Via Benzinga

The Schall Law Firm Encourages Stockholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud

December 15, 2024

Via ACCESSWIRE

Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Affected Investors Are Invited To Contact The Schall Law Firm

December 14, 2024

Via ACCESSWIRE

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.